Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Lasofoxifene May Improve Vaginal/Vulvar Symptoms in Postmenopausal ER+/HER2–, ESR1-Mutated Breast Cancer

March 6th 2023

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

March 6th 2023

The antibody-drug conjugate trastuzumab deruxtecan met the prespecified target for objective response rate and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial.

Role of a Pharmacist in the Multidisciplinary Approach to Identifying Biomarkers

March 6th 2023

Expert perspectives on the role of an oncologic pharmacist within a tumor board and how they can improve upon precision medicine in cancer management.

The Value of Molecular Tumor Boards and Multidisciplinary Care

March 6th 2023

Comprehensive discussion on the role of tumor boards—or more specifically, molecular tumor boards—in the optimal management of patients with cancer.

Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced Tumors

February 27th 2023

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Improving Uptake of Biomarker Testing and Precision Medicine in Cancer Care

February 27th 2023

Key opinion leaders in the field of cancer management discuss resistance to the uptake of biomarker testing and precision medicine, with deference to the community setting.

Optimizing the Timing and Utilization of Biomarker Testing in Cancer Care

February 27th 2023

Expert pathologist Samuel K. Caughron, MD, FCAP, shares best strategies for the timing and utilization of biomarker testing while managing patients with cancer.

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

Updating Biomarker Testing Strategies as Cancer Care Evolves

February 20th 2023

Timothy J. Pluard, MD; Ossama Tawfik, MD; and Sujith R. Kalmadi, MD, reflect on how they update their biomarker testing strategies as the field of cancer care and precision medicine evolves.

Armamentarium of Biomarker Testing Strategies in Cancer Care

February 20th 2023

Expert perspectives on the wide array of biomarker testing modalities available to patients receiving treatment for cancer.

Dr. Goel on the Evolution of Precision and Personalized Medicine in Cancer Care

February 16th 2023

Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.

Traveling Through the Lung Cancer Treatment Paradigm: Biomarker Guidance in NSCLC

February 15th 2023

In this second episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the need for additional circulating biomarkers beyond PD-L1 in non–small cell lung cancer.

Optimizing Cancer Care: Interpreting and Communicating Biomarker Testing Results

February 13th 2023

Comprehensive discussion on how best to interpret and document results from biomarker testing, along with considerations for communicating results with other healthcare professionals.

Addressing Barriers to Adequate Biomarker Testing in Cancer Care

February 13th 2023

Key opinion leaders highlight challenges to adequate biomarker testing in cancer care and consider the value of collaboration to overcome these barriers.

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Emma L. Barber, MD, emphasized the importance of the ongoing phase 3 PORTEC-4a trial, which is investigating the role of molecular risk profiles in determining whether patients with endometrial cancer should receive no adjuvant therapy, vaginal brachytherapy, or external beam radiotherapy.

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Elevation Oncology is pausing development of the human anti–HER3 IgG2 monoclonal antibody seribantumab, along with the phase 2 CRESTONE trial investigating the agent, in patients with advanced solid tumors harboring NRG1 fusions.

Targetable Mutations and Rearrangements in Lung Cancers

February 7th 2023

Expert participants share their perspective on the advent of precision medicine in lung cancer, following the discovery of several key driver mutations and alterations.

Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer

February 5th 2023

Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.

Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC

February 1st 2023

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.